Library / Weight and metabolic

Exenatide

Also known as Byetta, Bydureon, Exendin-4

Approved medicine

The first GLP-1 receptor agonist, a synthetic version of a peptide found in Gila monster saliva. Approved for type 2 diabetes.

Not approved in Australia. Exenatide is not on the Australian Register of Therapeutic Goods and is no longer marketed in the United States. Only a prescriber can decide whether a medicine suits you and at what dose. This page is information, not a recommendation.

Background

The first GLP-1 receptor agonist, a synthetic version of exendin-4, a peptide isolated in 1992 from the venom of the Gila monster lizard. It was developed by Amylin Pharmaceuticals and approved by the FDA in 2005 as Byetta.

How it is thought to work

It activates GLP-1 receptors, increasing insulin release when blood sugar is high, reducing glucagon and slowing stomach emptying. It also reduces food intake.

What is claimed, and the evidence

Claim	Evidence	Notes
Blood sugar control in adults with type 2 diabetes	Approved use	FDA label indication alongside diet and exercise.
Weight loss in people without diabetes	Human trials	A 24 week trial in 80 people with obesity found reduced food intake early on but no significant weight difference from placebo at 24 weeks. Not approved for weight loss.

Side effects

Effect	How often	Notes
Nausea	Common	44% vs 18% with placebo when added to metformin or a sulfonylurea; usually eases over time.
Vomiting and diarrhoea	Common	Each 13% vs 4 to 6% with placebo.
Feeling jittery, dizziness, headache, indigestion	Common	Listed among the most common reactions (5% or more).
Low blood sugar Serious	Common	Mainly when combined with sulfonylureas or insulin.
Acute pancreatitis, including fatal cases Serious	Rare	Label warning.
Immune mediated low platelets with serious bleeding Serious	Rare	Can be fatal; do not use again after it occurs.
Serious allergic reactions, kidney injury from dehydration, gallbladder disease Serious	Rare	Label warnings.

Warnings

Never share a pen between people, even with a new needle.
Tell the anaesthetist before surgery or sedation, as stomach contents may be inhaled.
The Byetta and Bydureon brands were discontinued in 2024; a generic remains approved in the US and no current ARTG entry was found.

Regulatory status

Australia: No current ARTG entry found (ARTG search, September 2026). Schedule 4 in the Poisons Standard.
United States: FDA approved (Byetta 2005) for type 2 diabetes; the Byetta and Bydureon BCise brands were discontinued in 2024, and a generic exenatide remains approved.

Sources

Also in Weight and metabolic

From the VialOwl library, reviewed 26 September 2026. For education and general information. It is not medical advice and not a recommendation to use Exenatide.